Hasil Pencarian - Johannes V. van Thienen

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges

    Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges oleh Evert S.M. van Aken, Yvette M. van der Linden, Johannes V. van Thienen, Adrianus J. de Langen, Corrie A.M. Marijnen, Monique C. de Jong

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

    Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma oleh Jorine de Haan, Johannes V. van Thienen, Michael Casaer, Rebekka A. Hannivoort, Kristel Van Calsteren, Minke van Tuyl, Mathilde M. van Gerwen, Anne Debeer, Frédéric Amant, Rebecca C. Painter

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune‐related adverse events of immune checkpoint inhibitors

    Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune‐related adverse events of immune checkpoint inhibitors oleh Lishi Lin, Aletta P. I. Houwink, Jolanda M. van Dieren, Esther K. Wolthuis, Johannes V. van Thienen, Michiel S. van der Heijden, John B. A. G. Haanen, Jos H. Beijnen, Alwin D. R. Huitema

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

    Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evi... oleh Elisabeth E. Fransen van de Putte, Luna van den Brink, Mohamed A. Mansour, Johannes C. van der Mijn, Sofie Wilgenhof, Johannes V. van Thienen, John B.A.G. Haanen, Ekaterini Boleti, Thomas Powles, Patricia J. Zondervan, Niels M. Graafland, Axel Bex

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma

    Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma oleh Diane van der Woude, Theo Rispens, Catharina M Korse, Sjoerd H van der Burg, Ellen Kapiteijn, John B A G Haanen, Winan J van Houdt, Els M E Verdegaal, Marij J P Welters, Jessica S W Borgers, Tineke J van Wesemael, Johannes V van Thienen, Kyra A Gelderman, Dirk J A R Moes

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs

    The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs oleh Hilin Yildirim, Christiaan V Widdershoven, Maureen JB Aarts, Axel Bex, Haiko J Bloemendal, Deirdre M Bochove-Overgaauw, Paul Hamberg, Karin H Herbschleb, Tom van der Hulle, Brunolf W Lagerveld, Martijn GH van Oijen, Sjoukje F Oosting, Johannes V van Thienen, Astrid AM van der Veldt, Hans M Westgeest, Evelijn E Zeijdner, Katja KH Aben, Corina van den Hurk, Patricia J Zondervan, Adriaan D Bins

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

    IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 muta... oleh Annegien Broeks, Sofie Wilgenhof, John B A G Haanen, Karolina Sikorska, Christian U Blank, Judith M Versluis, Jan Willem B de Groot, Esmee P Hoefsmit, Elisa A Rozeman, Petros Dimitriadis, Aysegul Sari, Daan van den Broek, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Stijn W T P J Heijmink, Marieke A Vollebergh, Johannes V van Thienen

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: